Accelerating Biomedical Progress in Europe: Strategic Management Consulting Insights

Life sciences generate an unusual combination of data volume and complexity. Molecular structures, genomic information, clinical records, imaging, laboratory results and manufacturing data each reveal different aspects of biology and medicine. Artificial intelligence can help connect these information streams, but its usefulness depends on whether the resulting insights can withstand scientific scrutiny. The U.S. Food and Drug Administration says the use of AI across the drug product lifecycle has increased significantly and now spans nonclinical research, clinical development, post-market activities and manufacturing. The agency has also developed specific principles for responsible AI use in drug development. Drug Discovery Moves from Prediction to Validation Drug discovery remains one of the most active areas for AI. Algorithms can examine molecular structures, biological relationships and experimental results to prioritize targets and compounds for laboratory investigation. That capability can narrow enormous search spaces. It does not, however, remove the biological complexity that makes drug development difficult. A recent Nature Reviews Drug Discovery perspective found that evidence of clinically meaningful impact from AI in drug discovery remains limited, citing challenges around clinical translation, complex life sciences data and poorly defined real-world use cases. This distinction is becoming important for pharmaceutical companies. The strongest AI programs are likely to be those measured by better scientific decisions rather than model performance alone. Prediction is useful only when researchers can test, interpret and act on the result. Clinical Development Gains New Tools Clinical trials generate another significant opportunity for AI. Patient selection, trial matching, data monitoring, endpoint analysis and recruitment can involve large datasets that are difficult to manage manually. Recent regulatory activity points toward greater experimentation. The FDA has announced initiatives to modernize clinical development, including an expedited IND pilot and work involving advanced quantitative methods. The agency has also been exploring AI-enabled technologies for improving the efficiency and quality of decision-making in early-stage trials. Digital health technologies are expanding the available evidence further. Wearable sensors, photography and contactless measurements can potentially collect information remotely during clinical investigations. The FDA opened a 2026 funding opportunity to study how these technologies could support drug development and improve data collection. Regulation Becomes Part of AI Strategy An AI system used in life sciences cannot be treated like a conventional enterprise software application. Its output may influence decisions concerning safety, efficacy or product quality. The FDA and European Medicines Agency issued ten guiding principles for good AI practice in drug development in January 2026. The principles emphasize humancentered design, risk-based assessment, clear context of use, multidisciplinary expertise, data governance, model evaluation and lifecycle management. “The science itself remains the anchor. AI can accelerate pattern recognition, support modeling and organize complex information, but it cannot replace experimental evidence or clinical validation.” The FDA has separately proposed a risk-based credibility framework for AI models used to generate information supporting regulatory decisions involving drugs and biological products. These developments place greater responsibility on companies to document how models are developed, validated and maintained. An algorithm may be technically impressive, but regulators need evidence that its use is appropriate for the specific purpose for which it generates information. Manufacturing Opens Another Frontier Pharmaceutical manufacturing produces continuous streams of process and quality information. AI and machine learning can examine this information for unusual patterns, process deviations and maintenance signals. The opportunity extends into generic drug development and manufacturing. During a 2026 FDA scientific workshop, researchers and industry representatives examined AI applications involving formulation, manufacturing, nitrosamine risk, quality systems and regulatory assessment. In production environments, the value of AI may therefore be less about replacing workers and more about giving specialists earlier visibility into problems. A system that identifies a developing deviation before it affects a batch can support faster investigation and more informed intervention. Data Quality Sets the Ceiling AI cannot compensate for fragmented or poorly governed data. Life sciences companies often operate across research, clinical, manufacturing and commercial environments that were built at different times and use different standards. Data governance consequently becomes part of the AI strategy. Information must have a clear origin, appropriate controls and sufficient context for the intended analysis. The FDA’s 2026 principles specifically identify data governance and documentation as core elements of responsible AI practice. Model development also requires clarity about the population and conditions under which a system is expected to perform. A model trained on one dataset may not automatically transfer to another laboratory, patient population or manufacturing environment. Human Expertise Remains Essential AI is unlikely to make scientific expertise less important. It changes where experts spend their time. Researchers can use computational systems to examine possibilities that would be difficult to explore manually, while scientists remain responsible for interpreting findings and designing experiments. Clinical teams can receive additional signals from data while retaining responsibility for patient-related decisions. Manufacturing specialists can use predictive information without abandoning established quality controls. Recent research on AI-enabled clinical trials similarly emphasizes fit-for-purpose validation, regulatory engagement and human oversight as central principles. That model of collaboration is likely to be more durable than attempts to automate entire scientific workflows without sufficient safeguards. From AI Adoption to Measurable Value The next stage of life science AI will be defined less by the number of tools adopted and more by the quality of outcomes they support. Pharmaceutical and biotechnology companies will need to establish clear use cases, reliable data foundations and evidence that AI improves decisions, productivity or development timelines. The science itself remains the anchor. AI can accelerate pattern recognition, support modeling and organize complex information, but it cannot replace experimental evidence or clinical validation. Life science AI is therefore entering a more disciplined period. The technology has moved beyond curiosity, yet its long-term value will depend on proving that computational capability translates into better scientific decisions and more reliable development. For an industry where evidence determines progress, that standard is not a limitation. It is the foundation for responsible adoption. ...Read more

Expanding production capacity is not always a matter of adding equipment. For companies involved in xenogenic biomaterial design and manufacturing across Europe, growth plans may be influenced by a less visible factor: access to specialized expertise. The sector operates at the intersection of biological science, manufacturing processes and quality oversight. That combination creates workforce requirements that can be difficult to satisfy, particularly as organizations expand development activities or move toward larger-scale production. Finding the right talent can be particularly difficult in specialized fields such as biomaterials. Companies often look for professionals who understand biological materials and can work within tightly controlled manufacturing environments. That combination of expertise is not always easy to find, which can make recruitment a lengthy process. The challenge does not end once a position is filled. As organizations grow, knowledge transfer becomes increasingly important. Processes and technical practices that may have started within small research teams often need to be documented, standardized and shared across larger operational groups. Without a structured approach to preserving and transferring that knowledge, sustaining growth can become more difficult. Bringing new people on board is only part of the challenge. Many employees require extensive onboarding before they are ready to take on responsibilities in specialized production settings. Because that preparation takes time, workforce readiness may not always keep pace with expansion ambitions. Leadership teams often face a practical balancing act between growth ambitions and workforce readiness. Expanding production too quickly can put strain on process execution and quality oversight if there are gaps in expertise. That can make talent availability an important consideration in decisions about when and how to scale operations. These workforce realities can have implications for buyers, too. Reliable production and consistent delivery often rely on the people behind the process. Because of that, organizations may want assurance that suppliers have the technical expertise and staffing capacity needed to support operations as requirements grow. Competitive pressures could intensify these concerns. As biomaterial development attracts continued interest, companies may find themselves competing for many of the same scientific and technical professionals. Retention may become nearly as important as recruitment. Under these conditions, educational institutions and industry may have an increasingly important role to play. Efforts to prepare and develop future talent could help manufacturers build the workforce they need while supporting the long-term growth of the sector. It also highlights a reality that can sometimes be overlooked. Advanced biomaterials are built on specialized knowledge as much as scientific innovation. New discoveries may create opportunities, but their success ultimately depends on having the expertise needed to bring them into reliable production environments. For Europe's xenogenic biomaterial sector, future growth may depend as much on workforce readiness as on technological progress. Expansion plans can move only as fast as organizations are able to build and maintain the expertise required to support them. ...Read more

Cell therapy product development is becoming more manufacturing-led as companies recognize that clinical promise can weaken if process design is not addressed early. Developers are moving beyond a research-first mindset and placing greater attention on scalability, product consistency, release testing and manufacturing evidence before late-stage trials. The market context supports this shift. The global cell therapy manufacturing market is estimated at USD 6.51 billion in 2026 and is projected to reach USD 17.65 billion by 2033, according to Coherent Market Insights. Growth is being shaped by demand across autologous and allogeneic therapies, along with development activity in oncology, musculoskeletal conditions, cardiovascular disease, neurological conditions and other areas. For developers, the manufacturing process looks very different depending on the type of therapy being produced. Autologous therapies require each patient's cells to be collected, processed and returned through a carefully coordinated, individualized workflow. Allogeneic therapies, by contrast, are designed for larger-scale production but bring their own challenges around batch manufacturing and immune compatibility. In both cases, success depends on building manufacturing processes that are reliable enough to support clinical development while remaining practical to scale as therapies move toward commercialization. The problem often appears when early research methods are carried too far into development. Manual steps may work in a small study, but become difficult to reproduce later. A release assay may be acceptable for early-stage work but insufficient for a broader program. Raw material variation can also affect performance if it is not understood early. Regulators are placing more attention on chemistry, manufacturing and controls. The FDA issued final guidance in May 2026 on CMC flexibilities for human cellular and gene therapy products being developed for biologics license applications. The guidance describes how the agency applies flexibility to CMC requirements under BLA development. Developers still need to show that the product can be made consistently and that critical quality attributes are understood. Process changes during development must be justified and documented. Sponsors that wait too long to define their manufacturing strategy may face comparability questions that slow progress. Technology is also changing the development environment. At BIO 2026, cell and gene therapy companies discussed using AI and data systems to improve manufacturing work, pointing to a sector where digital tools are becoming more relevant to production learning. The business implication is clear. Cell therapy product development is no longer only about biology and clinical response. It is also about whether a company can build a repeatable product pathway. The next phase will favor developers who treat manufacturing as part of product identity from the start. In cell therapy, a strong clinical idea must be supported by a process that can survive scale, scrutiny and real patient delivery. ...Read more

Clinical research in gastroenterology is becoming more specialised as studies address complex digestive disorders, varied patient populations and increasingly precise treatment approaches. Gastroenterology CRO services support pharmaceutical and biotechnology companies by coordinating clinical trial activities such as patient recruitment, site management, data collection and regulatory documentation. In Europe, these services can help sponsors navigate diverse healthcare systems while maintaining consistent study processes across multiple countries. Specialised CRO support can also improve trial coordination, strengthen data quality and reduce operational pressure on research teams, helping sponsors maintain greater focus on clinical development and patient outcomes. Current Market Trends and Technological Advancements Demand is rising for trials targeting inflammatory bowel disease, irritable bowel syndrome, metabolic liver disorders, gastrointestinal cancers and other complex conditions. Sponsors are increasingly looking for disease-specific expertise, stronger patient engagement and trial designs that reflect diverse clinical populations. Europe continues to support significant gastrointestinal research activity through its established clinical research ecosystem and specialised investigator networks.  Hybrid and decentralised trial models are gaining wider use in suitable gastroenterology studies. Remote consultations, electronic patient-reported outcomes, home-based assessments and wearable devices can reduce unnecessary site visits while keeping participants connected to research teams. Digital recruitment methods are also helping sponsors reach broader pools of potential participants. Machine learning and advanced analytics are evolving into powerful tools across the breadth of clinical research operations. These technologies can support patient identification, medical data analysis, risk-based monitoring and automated data checks. AI-assisted analysis of endoscopic images is also emerging as a valuable capability for studies where visual assessments contribute to treatment evaluation.  Cloud-based trial platforms, electronic data capture and real-world data integration are further reshaping research workflows. Connected systems can improve access to study information and support faster review of clinical data. Stronger focus on data privacy, traceability and regulatory compliance is also encouraging CROs to adopt secure digital infrastructure as gastroenterology research becomes increasingly data-driven. Key Challenges and Solutions in Gastroenterology CRO Services The eligibility criteria in some studies may be very complex, making it difficult to find participants with all the qualifications, especially in trials that target participants with particular levels of disease, previous treatments and coexisting conditions. This can affect enrollment timelines and limit the representativeness of study populations. Gastroenterology CRO services can address this through detailed feasibility assessments, targeted site selection, investigator input and early screening strategies that identify suitable participants more efficiently. Current clinical trial guidance also emphasises enrolling populations that reflect the characteristics of patients likely to receive the treatment.  “Specialised CRO support can also improve trial coordination, strengthen data quality and reduce operational pressure on research teams.” Selecting meaningful clinical endpoints presents another challenge because gastrointestinal disorders can involve symptoms, objective findings and changes in disease activity that do not always move together. In conditions such as inflammatory bowel disease, clinical response and endoscopic measures may both contribute to treatment assessment. CRO teams can help sponsors establish clear endpoint frameworks, standardised assessment procedures and appropriate measurement schedules before a study begins. Careful endpoint planning can also reduce ambiguity during statistical analysis and regulatory review. Sustaining engagement of participants in clinical trials over an extended period may prove challenging in cases where the protocols include repetitive testing, intrusive procedures, dietary considerations and extended follow-up periods. Missed visits and incomplete assessments can affect the completeness of trial results. Clear participant communication, well-organised visit schedules, investigator training and timely follow-up can help reduce avoidable disruptions. CROs can also work with study sites to identify recurring participation barriers and adjust operational practices within the approved protocol. Protocol complexity has the potential to impose significant burdens on investigators and research coordinators, especially in studies incorporating multiple assessment endpoints with elaborate safety parameters. However, differences in the performance of procedures may lead to variability between participating sites. Standard operating procedures (SOPs), centralised training, periodic quality reviews and defined escalation pathways can reinforce consistency. In Europe, coordinated oversight is particularly valuable when studies involve investigators operating under different national healthcare and research environments.  When investigational therapies are evaluated in patients with chronic gastrointestinal diseases who may also be taking other medications, safety monitoring continues to be an important responsibility. Distinguishing treatment-related events from symptoms associated with the underlying disease can require careful clinical assessment. Experienced medical monitoring teams, predefined safety criteria, consistent adverse-event documentation and prompt review of emerging signals can support more reliable safety oversight. A structured approach helps research teams respond appropriately while preserving the integrity of the study. Future Prospects Shaping Gastroenterology CRO Services   The next phase of gastroenterology research is expected to place greater emphasis on precision medicine and biomarker-driven development. Advances in genetic, molecular, immune and microbiome research could support more targeted treatment strategies and refined patient stratification. This may increase demand for CRO expertise in biomarker studies, translational research and specialised clinical programs. Greater collaboration among pharmaceutical companies, research institutions, specialist investigators and international networks is likely to shape future clinical development. Europe can play an important role through its established research ecosystem and multinational collaborations. Gastroenterology CRO services may consequently expand toward specialised scientific support, helping sponsors navigate increasingly complex development programs and individualised treatment approaches.    ...Read more